Apremilast in Patients With Moderate to Severe Palmoplantar Pustulosis (PPP) (APLANTUS)
Status:
Completed
Trial end date:
2019-08-29
Target enrollment:
Participant gender:
Summary
Multicenter, open-label, single-arm, phase II, pilot study. The screening period was up to 4
weeks and treatment took place over 20 weeks per patient. Five visits per patient were
performed including: Visit 1 at week -4 to -1 (screening), Visit 2 at week 0 (baseline),
Visit 3 at week 4, Visit 4 at week 12, and Visit 5 at week 20 (end of study). There was no
follow-up period.